Four in five docs support ad moratorium

Share this article:
Over 80 percent of physicians surveyed believe it is a good idea to prohibit DTC advertising for new prescription drugs for a period of time after the FDA approval to allow doctors time to gain familiarity with the medications, according to a recent study.
Research firm HRA conducted the study by surveying 2,015 physicians in their analysis.
While more than four out of five physicians favored some type of ban on DTC for all new prescription drugs, there was less agreement on the type of ban that they would be most likely to support.
Forty-three percent favor a mandatory ban for some limited period of time. Thirty-three percent favor a voluntary ban with each pharmaceutical company deciding when to begin advertising to consumers, and 24 percent say no ban on DTC advertising is necessary.
Other key findings of the survey included:
•Fifty-six percent of the doctors noted that they get one to five calls a week to discuss DTC-advertised drugs or schedule an appointment to discuss a DTC-advertised drug.
•Sixty-five percent of the doctors stated that patients initiate discussions about DTC-advertised prescription drug products. 
•Sixty-four percent of the physicians get one to five patient requests per week for DTC-advertised drugs.
•Nearly two-thirds, 62 percent, of the surveyed doctors stated that they prescribe the discussed medication only one-quarter of the time or less, with nearly 40 percent of those writing a prescription 10 percent, or less, of the time.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...